ArticleMolecular biology reports2026
Relationship between BDNF rs6265 (VAL66MET) polymorphism and serum BDNF LEVELS in anxiety disorders.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study investigated serum Brain-Derived Neurotrophic Factor (BDNF) levels and the BDNF rs6265 (Val66Met) polymorphism in patients with anxiety disorders compared to healthy controls, and examined their relationship with symptom severity to clarify their role in anxiety etiology.
methodsThe study included 64 patients diagnosed with anxiety disorders and 64 healthy controls. Clinical assessments were performed using the Hamilton Anxiety Rating Scale (HAM-A), Hospital Anxiety and Depression Scale (HADS), and Level 2 Somatic Symptom Scale. Serum BDNF levels were measured using ELISA, and rs6265 polymorphism genotyping was performed via RT-PCR.
resultsMedian serum BDNF levels were significantly lower in the patient group compared to controls [1.50 (0.19-3.28) ng/mL vs. 1.62 (1.05-9.50) ng/mL; p = 0.007]. Significant negative correlations were found between serum BDNF levels and scores on the HAM-A (rs= -0.386), HADS (rs= -0.317), and Level 2 Somatic Symptom Scale (rs= -0.224) (p < 0.01 for all). ROC analysis identified a BDNF cutoff value of 1.54 ng/mL for predicting anxiety disorders (sensitivity: 59.4%, specificity: 57.8%, AUC: 0.639; 95% CI: 0.544-0.735). No significant differences were observed between groups regarding Val66Met genotype distribution (p = 0.843), nor was there a significant association between the polymorphism and serum BDNF levels (p = 0.215).
conclusionOur findings demonstrate that decreased serum BDNF levels are associated with the presence and symptom severity of anxiety disorders. However, the Val66Met polymorphism does not appear to be a primary determinant of serum BDNF levels in this population, suggesting that other genetic or environmental factors may be involved.
Indexed as
Identifiers
42479327What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.